FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Oliver Ottmann

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Physiology

Concepts & Ideas

Treatment Outcome

Procedures

Co-author Network

Publications

TOP 3
Francis J Giles; Michele Baccarani; Philipp D le Coutre; Oliver G Ottmann; William M Sallas; Richard C Woodman; Ophelia Q P Yin; Hagop M Kantarjian
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
F Thol; Marry M van den Heuvel-Eibrink; K Wagner; Gesine Bug; F Damm; Arnold Ganser; Gudrun Göhring; Wolf-Karsten Hofmann; I H I Hollink; B Kölking; Jürgen Krauter; C Michel Zwaan; M Morgan; Oliver G Ottmann; Brigitte Schlegelberger; Michael Heuser
Analysis of NUP98/NSD1 translocations in adult AML and MDS patients.
Max S Topp; Andreas Viardot; Gerhard Zugmaier; Patrick A Baeuerle; Monika Brüggemann; Thomas Burmeister; Evelyn Degenhard; Hermann Einsele; Marie-Elisabeth Goebeler; Nicola Gökbuget; Dieter Hoelzer; Heinz A Horst; Matthias Klinger; Michael Kneba; Rudolf Köhne-Volland; Peter Kufer; Dirk Nagorsen; Svenja A Neumann; Oliver G Ottmann; Thorsten Raff; Gert Riethmüller; Markus Schaich; Margit Schmidt; Matthias Stelljes; Ralf C Bargou
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Oliver Ottmann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Francis J Giles; Michele Baccarani; Philipp D le Coutre; Oliver G Ottmann; William M Sallas; Richard C Woodman; Ophelia Q P Yin; Hagop M Kantarjian
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
European journal of clinical pharmacology 2013;69(4):813-23.
2013: F Thol; Marry M van den Heuvel-Eibrink; K Wagner; Gesine Bug; F Damm; Arnold Ganser; Gudrun Göhring; Wolf-Karsten Hofmann; I H I Hollink; B Kölking; Jürgen Krauter; C Michel Zwaan; M Morgan; Oliver G Ottmann; Brigitte Schlegelberger; Michael Heuser
Analysis of NUP98/NSD1 translocations in adult AML and MDS patients.
Leukemia 2013;27(3):750-4.
2012: Max S Topp; Andreas Viardot; Gerhard Zugmaier; Patrick A Baeuerle; Monika Brüggemann; Thomas Burmeister; Evelyn Degenhard; Hermann Einsele; Marie-Elisabeth Goebeler; Nicola Gökbuget; Dieter Hoelzer; Heinz A Horst; Matthias Klinger; Michael Kneba; Rudolf Köhne-Volland; Peter Kufer; Dirk Nagorsen; Svenja A Neumann; Oliver G Ottmann; Thorsten Raff; Gert Riethmüller; Markus Schaich; Margit Schmidt; Matthias Stelljes; Ralf C Bargou
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
Blood 2012;120(26):5185-7.
2012: Tobias Berg; Gesine Bug; Oliver G Ottmann; Klaus Strebhardt
Polo-like kinases in AML.
Expert opinion on investigational drugs 2012;21(8):1069-74.
2012: Heike Pfeifer; M Schmalzing; A Schmidt; Hubert Serve; Matthias Stelljes; Barbara Wassmann; Lydia Wunderle; S Wystub; Anja Binckebanck; Patrick Brück; Ulrich Dührsen; Aristoteles Giagounidis; Dieter Hoelzer; Thoralf Lange; J Maier; Oliver G Ottmann
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Leukemia 2012;26(7):1475-81.
2012: Afsar A Mian; Yousef Najajreh; Oliver G Ottmann; Jamal Mahajna; Anna Metodieva; Martin Ruthardt
p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.
Haematologica 2012;97(2):251-7.
2012: Gianni Capalbo; Dieter Hoelzer; Thea Müller-Kuller; Oliver G Ottmann; Urban J Scheuring
HIV-1 infection suppresses expression of host cell cycle-associated gene PDS5A.
Intervirology 2012;55(4):263-75.
2011: Ruriko Tanaka; Hisashi Wakita; Hisayuki Yao; Mariko Yoshimura; Eishi Ashihara; Yoshihiro Hayashi; Hideyo Hirai; Kuniaki Itoh; Shinya Kimura; Junia V Melo; Rina Nagao; Kaichi Nishiwaki; Oliver G Ottmann; Sakiko Satake; Ken-Ichi Sawada; Kenshi Suzuki; Naoto Takahashi; Taira Maekawa
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.
Cancer letters 2011;312(2):228-34.
2011: Gianni Capalbo; Ursula Dietrich; Dieter Hoelzer; Stefan A Klein; Sandra Markovic; Thea Mueller-Kuller; Oliver G Ottmann; Urban J Scheuring
Knockdown of ERM family member moesin in host cells increases HIV type 1 replication.
AIDS research and human retroviruses 2011;27(12):1317-22.
2011: Andrea Kuendgen; Kathrin Nachtkamp; Judith Neukirchen; Oliver G Ottmann; Julie Schanz; Ulrich Germing; Rainer Haas; Detlef Haase; Barbara Hildebrandt; Gesine Bug; Ariane Dienst; Norbert Gattermann
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.
Clinical epigenetics 2011;2(2):389-99.
2011: Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Blood 2011;117(4):1141-5.
2010: Gesine Bug; Oliver G Ottmann
The DAC system and associations with acute leukemias and myelodysplastic syndromes.
Investigational new drugs 2010;28 Suppl 1():S36-49.
2010: Gianni Capalbo; Thea Müller-Kuller; Ursula Dietrich; Dieter Hoelzer; Oliver G Ottmann; Urban J Scheuring
Inhibition of X4-tropic HIV type 1 replication by knockdown of the cellular protein LEREPO4.
AIDS research and human retroviruses 2010;26(10):1155-61.
2010: Felicitas Thol; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Frederik Damm; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver G Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Arnold Ganser; Michael Heuser
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.
Haematologica 2010;95(10):1668-74.
2010: Ruriko Tanaka; Matthew S Squires; Shinya Kimura; Asumi Yokota; Rina Nagao; Takahiro Yamauchi; Miki Takeuchi; Hisayuki Yao; Matthias Reule; Tomoko Smyth; John F Lyons; Neil T Thompson; Eishi Ashihara; Oliver G Ottmann; Taira Maekawa
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Blood 2010;116(12):2089-95.
2010: Saskia Gueller; Martina Komor; Daniel Nowak; Claudia D Baldus; Sven de Vos; Dieter Hoelzer; Oliver G Ottmann; Wolf-Karsten Hofmann
Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome.
Experimental hematology 2010;38(9):718-32, 732.e1-6.
2010: Andrew Lamb; Phillipp le Coutre; Jorge Cortes; Javier Pinilla-Ibarz; Arnon Nagler; Andreas Hochhaus; Shinya Kimura; Oliver G Ottmann
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Cancer 2010;116(11):2665-72.
2010: Katharina Wagner; Frederik Damm; Gudrun Göhring; Kerstin Görlich; Michael Heuser; Irina Schäfer; Oliver G Ottmann; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna A Raghavachar; Walter Fiedler; Hartmut H Kirchner; Wolfram Brugger; Manuela Zucknick; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Jürgen Krauter
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(14):2356-64.
2010: Michael B Lilly; Oliver G Ottmann; Neil P Shah; Richard A Larson; Josy J Reiffers; Gerhard Ehninger; Martin C Müller; Aude Charbonnier; Eduardo Bullorsky; Herve Dombret; Mary Brigid Bradley-Garelik; Chao Zhu; Giovanni Martinelli
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
American journal of hematology 2010;85(3):164-70.
2010: Frederik Damm; Michael Heuser; Michael Morgan; Haiyang Yun; Anika Grosshennig; Gudrun Göhring; Brigitte Schlegelberger; Konstanze Döhner; Oliver G Ottmann; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna Raghavachar; Walter Fiedler; Hartmut Kirchner; Hartmut Döhner; Gerhard Heil; Arnold Ganser; Jürgen Krauter
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):578-85.
2010: Gianni Capalbo; Thea Müller-Kuller; Ursula Dietrich; Dieter Hoelzer; Oliver G Ottmann; Urban J Scheuring
Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression.
Retrovirology 2010;7():26.
2009: A A Mian; C Oancea; Z Zhao; Oliver G Ottmann; Martin Ruthardt
Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL.
Leukemia 2009;23(12):2242-7.
2009: Michael Dickinson; David Ritchie; Daniel J DeAngelo; Andrew Spencer; Oliver G Ottmann; Thomas Fischer; Kapil N Bhalla; Angela Liu; Katie Parker; Jeffrey W Scott; Mark J Bishton; H Miles Prince
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
British journal of haematology 2009;147(1):97-101.
2009: A A Mian; M Schüll; Z Zhao; C Oancea; A Hundertmark; Tim Beissert; Oliver G Ottmann; Martin Ruthardt
The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.
Leukemia 2009;23(9):1614-21.
2009: Oliver G Ottmann; Heike Pfeifer
First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.
Current opinion in oncology 2009;21 Suppl 1():S43-6.
2009: Bart A Nijmeijer; Karoly Szuhai; Henriëtte M Goselink; Marianke L J van Schie; Marja van der Burg; Danielle de Jong; Erik W A Marijt; Oliver G Ottmann; Roel Willemze; J H Frederik Falkenburg
Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors.
Experimental hematology 2009;37(3):376-85.
2009: Oliver G Ottmann; Heike Pfeifer
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2009;():371-81.
2009: Patricia Mambou Gwanmesia; Annette Romanski; Kerstin Schwarz; Biserka Bacic; Martin Ruthardt; Oliver G Ottmann
The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
BMC cancer 2009;9():53.
2008: Joerg Baeumler; Karoly Szuhai; J H Frederik Falkenburg; Marianke L J van Schie; Oliver G Ottmann; Bart A Nijmeijer
Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.
Cancer genetics and cytogenetics 2008;185(1):37-42.
2008: Iman Jilani; Andrew Lamb; Homan Faraji; Mercedes Gorre; Jorge Cortes; Oliver G Ottmann; Kapil N Bhalla; Susan O'Brien; Francis Giles; Maher Albitar
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
Leukemia research 2008;32(6):936-43.
2008: Paul La Rosée; Susanne Holm-Eriksen; Heiko Konig; Nicolai Härtel; Thomas Ernst; Julia Debatin; Martin C Mueller; Philipp Erben; Anja Binckebanck; Lydia Wunderle; Yaping Shou; Margaret Dugan; Rüdiger Hehlmann; Oliver G Ottmann; Andreas Hochhaus
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Haematologica 2008;93(5):765-9.
2008: Iman Jilani; Andrew Lamb; Mercedes Gorre; Jorge Cortes; Oliver G Ottmann; Kapil N Bhalla; Francis Giles; Maher Albitar
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Leukemia research 2008;32(4):643-9.
2008: Philipp le Coutre; Oliver G Ottmann; Francis Giles; Dong-Wook Kim; Jorge Cortes; Norbert Gattermann; Jane F Apperley; Richard A Larson; Elisabetta Abruzzese; Stephen G O'Brien; Kazimierz Kuliczkowski; Andreas Hochhaus; Francois-Xavier Mahon; Giuseppe Saglio; marco gobbi; Yok-Lam Kwong; Michele Baccarani; Timothy Hughes; giovanni martinelli; Jerald P Radich; Ming Zheng; Yaping Shou; Andrew Lamb
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Blood 2008;111(4):1834-9.
2008: Francis Giles; Daniel J DeAngelo; Michele Baccarani; Michael W N Deininger; françois guilhot; Timothy Hughes; Michael J Mauro; Jerald Radich; Oliver G Ottmann; Jorge Cortes
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Seminars in oncology 2008;35(1 Suppl 1):S1-17; quiz S18-20.
2007: Jonathan Singer; Y Shou; Francis Giles; H M Kantarjian; Y Hsu; A S Robeva; Patricia Rae; A Weitzman; J M Meyer; M Dugan; Oliver G Ottmann
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.
Leukemia 2007;21(11):2311-5.
2007: Gesine Bug; Konstantinos Anargyrou; Torsten Tonn; Heike Bialleck; Erhard Seifried; Dieter Hoelzer; Oliver G Ottmann
Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis.
Transfusion 2007;47(10):1843-50.
2007: Oliver G Ottmann; Hervé Dombret; giovanni martinelli; Bengt Simonsson; françois guilhot; Richard A Larson; Giovanna Rege-Cambrin; Jerald P Radich; Andreas Hochhaus; Anne Marie Apanovitch; Ashwin Gollerkeri; Steven Coutre
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Blood 2007;110(7):2309-15.
2007: Heike Pfeifer; Barbara Wassmann; Anna Pavlova; Lydia Wunderle; Johannes Oldenburg; Anja Binckebanck; Thoralf Lange; Andreas Hochhaus; Silvia Wystub; Patrick Brück; Dieter Hoelzer; Oliver G Ottmann
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood 2007;110(2):727-34.
2007: Oliver G Ottmann; Gesine Bug; Jürgen Krauter
Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia.
Seminars in hematology 2007;44(3):183-92.
2007: Kai Uwe Chow; Daniel Nowak; Bettina Trepohl; Simone Hochmuth; Bernd Schneider; Dieter Hoelzer; Paris S Mitrou; Lothar Bergmann; Oliver G Ottmann; Simone Boehrer
The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines.
Leukemia & lymphoma 2007;48(7):1379-88.
2007: Martin C Müller; Guiseppe Saglio; Feng Lin; Heike Pfeifer; Richard D Press; Raymond R Tubbs; Peter Paschka; Enrico Gottardi; Steven G O'Brien; Oliver G Ottmann; Hubertus Stockinger; Lothar Wieczorek; Kirsten Merx; Heiko König; Uwe Schwindel; Rüdiger Hehlmann; Andreas Hochhaus
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.
Haematologica 2007;92(7):970-3.
2007: Stefan Pursche; Oliver G Ottmann; Gerhard Ehninger; Eberhard Schleyer
High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;852(1-2):208-16.
2007: Oliver G Ottmann; Barbara Wassmann; Heike Pfeifer; Aristoteles Giagounidis; Matthias Stelljes; Ulrich Dührsen; Marc Schmalzing; Lydia Wunderle; Anja Binckebanck; Dieter Hoelzer
Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Cancer 2007;109(10):2068-76.
2007: Stefan Fruehauf; Julian Topaly; Eike C Buss; Thomas Fischer; Oliver G Ottmann; Bertold Emmerich; Martin C Müller; Peter Schuld; Leopold Balleisen; Rüdiger Hehlmann; Anthony Ho; Andreas Hochhaus
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Cancer 2007;109(8):1543-9.
2007: Jorge Cortes; Philippe Rousselot; Dong-Wook Kim; Ellen Ritchie; Nelson Hamerschlak; Steven Coutre; Andreas Hochhaus; françois guilhot; Giuseppe Saglio; Jane Apperley; Oliver G Ottmann; Neil Shah; Philipp Erben; Susan Branford; Prasheen Agarwal; Ashwin Gollerkeri; Michele Baccarani
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Blood 2007;109(8):3207-13.
2007: Gesine Bug; Kerstin Schwarz; Claudia Schoch; Manuela Kampfmann; Reinhard Henschler; Dieter Hoelzer; Oliver G Ottmann; Martin Ruthardt
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.
Haematologica 2007;92(4):542-5.
2007: Cornelius Miething; Rebekka Grundler; Claudia Mugler; Simone Brero; Josef Hoepfl; Jochen Geigl; Michael R Speicher; Oliver G Ottmann; Christian Peschel; Justus Duyster
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(11):4594-9.
2007: Christian Wichmann; Linping Chen; Markus Heinrich; Daniela Baus; Edith Pfitzner; Martin Zörnig; Oliver G Ottmann; Manuel Grez
Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Cancer research 2007;67(5):2280-9.
2007: Steffen Koschmieder; Shuchi Agrawal; Hanna S Radomska; Claudia S Huettner; Daniel G Tenen; Oliver G Ottmann; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiation.
International journal of oncology 2007;30(2):349-55.
2006: W Ma; Andrew Lamb; Iman Jilani; Mercedes Gorre; Kapil N Bhalla; Oliver G Ottmann; Francis Giles; Maher Albitar
Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
Leukemia 2006;20(11):1989-91.
2006: Junya Kuroda; Hamsa Puthalakath; Mark Cragg; Priscilla N Kelly; Philippe Bouillet; David C S Huang; Shinya Kimura; Oliver G Ottmann; Brian J Druker; Andreas Villunger; Andrew W Roberts; Andreas Strasser
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(40):14907-12.
2006: Barbara Wassmann; Heike Pfeifer; Nicola Goekbuget; Dietrich W Beelen; Joachim Beck; Matthias Stelljes; Martin Bornhäuser; Albrecht Reichle; Jolanta B Perz; Rainer Haas; Arnold Ganser; Mathias Schmid; Lothar Kanz; Georg Lenz; Martin Kaufmann; Anja Binckebanck; Patrick Brück; Regina Reutzel; Harald Gschaidmeier; Stefan Schwartz; Dieter Hoelzer; Oliver G Ottmann
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood 2006;108(5):1469-77.
2006: Andrew Lamb; Francis Giles; Lydia Wunderle; Kapil N Bhalla; Susan O'Brien; Barbara Wassmann; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Andreas Hochhaus; James D Griffin; Dieter Hoelzer; Maher Albitar; Margaret Dugan; Jorge Cortes; Leila Alland; Oliver G Ottmann
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
The New England journal of medicine 2006;354(24):2542-51.
2006: Noriko Koyama; Steffen Koschmieder; Sandhya Tyagi; Ignacio Portero-Robles; Jörg Chromic; Silke Myloch; Heike Nürnberger; Tanja Rossmanith; Wolf-Karsten Hofmann; Dieter Hoelzer; Oliver G Ottmann
Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2025-31.
2006: Dali Cai; Ying Wang; Oliver G Ottmann; Peter J Barth; Andreas Neubauer; Andreas Burchert
FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment.
Blood 2006;107(5):2094-7.
2005: Gesine Bug; Markus Ritter; Barbara Wassmann; Claudia Schoch; Thorsten Heinzel; Kerstin Schwarz; Annette Romanski; Oliver H Kramer; Manuela Kampfmann; Dieter Hoelzer; Andreas Neubauer; Martin Ruthardt; Oliver G Ottmann
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Cancer 2005;104(12):2717-25.
2005: Martina Komor; Saskia Güller; Claudia D Baldus; Sven de Vos; Dieter Hoelzer; Oliver G Ottmann; Wolf-Karsten Hofmann
Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation.
Stem cells (Dayton, Ohio) 2005;23(8):1154-69.
2005: Hidekazu Segawa; Shinya Kimura; Junya Kuroda; Kiyoshi Sato; Asumi Yokota; Eri Kawata; Yuri Kamitsuji; Eishi Ashihara; Takeshi Yuasa; Yoshihide Fujiyama; Oliver G Ottmann; Taira Maekawa
Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth.
British journal of haematology 2005;130(4):558-60.
2005: Elena Puccetti; Xiaomin Zheng; Daria Brambilla; Anita Seshire; Tim Beissert; Simone Boehrer; Heike Nürnberger; Dieter Hoelzer; Oliver G Ottmann; Clara Nervi; Martin Ruthardt
The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.
Cancer research 2005;65(14):6080-8.
2005: Barbara Wassmann; Heike Pfeifer; Michael Stadler; Martin Bornhaüser; Gesine Bug; Urban J Scheuring; Patrick Brück; Matthias Stelljes; Rainer Schwerdtfeger; Nadezda Basara; Jolanta B Perz; Donald Bunjes; Georg Ledderose; Rolf Mahlberg; Anja Binckebanck; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood 2005;106(2):458-63.
2005: Gesine Bug; Hilal Gül; Kerstin Schwarz; Heike Pfeifer; Manuela Kampfmann; Xiaomin Zheng; Tim Beissert; Simone Boehrer; Dieter Hoelzer; Oliver G Ottmann; Martin Ruthardt
Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells.
Cancer research 2005;65(7):2537-41.
2005: Annette Romanski; Gesine Bug; Sven Becker; Manuela Kampfmann; Erhard Seifried; Dieter Hoelzer; Oliver G Ottmann; Torsten Tonn
Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
Experimental hematology 2005;33(3):344-52.
2005: Walter Fiedler; Hubert Serve; Hartmut Döhner; Michael Schwittay; Oliver G Ottmann; Anne-Marie O'Farrell; Carlo Bello; Randy Allred; William C Manning; Julie M Cherrington; Sharianne G Louie; Weiru Hong; Nicoletta M Brega; Giorgio Massimini; Paul Scigalla; Wolfgang E Berdel; Dieter K Hossfeld
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Blood 2005;105(3):986-93.
2005: Oliver G Ottmann; Barbara Wassmann
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2005;():118-22.
2004: Patrick Brück; Barbara Wassmann; Elizabeth Ramos Lopez; Dieter Hoelzer; Oliver G Ottmann
Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms.
Leukemia research 2004;28(11):1153-7.
2004: Wolf-Karsten Hofmann; G Heil; C Zander; S Wiebe; Oliver G Ottmann; Lothar Bergmann; K Hoeffken; JT Fischer; A Knuth; K Kolbe; H J Schmoll; W Langer; M Westerhausen; C B Koelbel; Dieter Hoelzer; Arnold Ganser
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Annals of hematology 2004;83(8):498-503.
2004: Gerd Munzert; Dieter Kirchner; Oliver G Ottmann; Lothar Bergmann; Roland M Schmid
Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Leukemia & lymphoma 2004;45(6):1181-4.
2004: Xiaomin Zheng; Tim Beissert; Natasa Kukoc-Zivojnov; Elena Puccetti; Joachim Altschmied; Corinna Strolz; Simone Boehrer; Hilal Gul; Orinta Schneider; Oliver G Ottmann; Dieter Hoelzer; Reinhard Henschler; Martin Ruthardt
Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells.
Blood 2004;103(9):3535-43.
2004: Wolf-Karsten Hofmann; Martina Komor; Dieter Hoelzer; Oliver G Ottmann
Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia.
Leukemia & lymphoma 2004;45(4):655-60.
2004: Annette Romanski; Biserka Bacic; Gesine Bug; Heike Pfeifer; Hilal Gul; Stacy W Remiszewski; Dieter Hoelzer; Peter Atadja; Martin Ruthardt; Oliver G Ottmann
Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Haematologica 2004;89(4):419-26.
2004: Philipp le Coutre; Karl-Anton Kreuzer; Stefan Pursche; Malte v Bonin; Traugott Leopold; Gökben Baskaynak; Bernd Dörken; Gerhard Ehninger; Oliver G Ottmann; Andreas Jenke; Martin Bornhäuser; Eberhard Schleyer
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
Cancer chemotherapy and pharmacology 2004;53(4):313-23.
2004: Noriko Koyama; Dieter Hoelzer; Oliver G Ottmann
Regulation of human IL-18 gene expression: interaction of PU.1 with GC-box binding protein is involved in human IL-18 expression in myeloid cells.
European journal of immunology 2004;34(3):817-26.
2004: Barbara Wassmann; Heike Pfeifer; Urban J Scheuring; Anja Binckebanck; Nicola Gökbuget; Johannes Atta; Patrick Brück; Harald Rieder; Claudia Schoch; Lothar Leimer; Rainer Schwerdtfeger; Gerhard Ehninger; Thomas Lipp; Jolanta B Perz; Matthias Stelljes; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Blood 2004;103(4):1495-8.
2004: Junya Kuroda; Shinya Kimura; Hidekazu Segawa; Kiyoshi Sato; Seiji Matsumoto; Masaki Nogawa; Takeshi Yuasa; Yutaka Kobayashi; Toshikazu Yoshikawa; Oliver G Ottmann; Taira Maekawa
p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
Cancer science 2004;95(2):186-92.
2004: Eberhard Schleyer; Stefan Pursche; Claus-Henning Köhne; Ulrich Schuler; Ulf Renner; Harald Gschaidmeier; Jens Freiberg-Richter; Traugott Leopold; Andreas Jenke; M Bonin; T Bergemann; Philipp le Coutre; M Gruner; Martin Bornhäuser; Oliver G Ottmann; Gerhard Ehninger
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;799(1):23-36.
2004: Martin Bornhäuser; Thomas Illmer; Philipp le Coutre; J Pursche; M von Bonin; Jens Freiberg-Richter; Markus Schaich; Uwe Platzbecker; Christian Thiede; Oliver G Ottmann; Ch Köhne; Jan Braess; Gerhard Ehninger; Eberhard Schleyer
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.
Annals of hematology 2004;83 Suppl 1():S61-4.
2004: Shinya Kimura; Junya Kuroda; Hidekazu Segawa; Kiyoshi Sato; Masaki Nogawa; Takeshi Yuasa; Oliver G Ottmann; Taira Maekawa
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
International journal of hematology 2004;79(1):37-43.
2003: Jürgen Krauter; Kerstin Gorlich; Oliver G Ottmann; Michael Lubbert; Hartmut Dohner; Wolfgang Heit; Lothar Kanz; Arnold Ganser; Gerhard Heil
Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4413-22.
2003: Martin C Müller; Norbert Gattermann; Tanja Lahaye; Michael W N Deininger; A Berndt; Stefan Fruehauf; Andreas Neubauer; Thomas Fischer; Dieter K Hossfeld; Folker Schneller; S W Krause; Christoph Nerl; Herbert G Sayer; Oliver G Ottmann; C Waller; Walter Aulitzky; Philipp le Coutre; Mathias Freund; Kirsten Merx; Peter Paschka; Heiko König; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Leukemia 2003;17(12):2392-400.
2003: Barbara Wassmann; Nicola Gökbuget; Urban J Scheuring; Anja Binckebanck; Regina Reutzel; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
Annals of hematology 2003;82(11):716-20.
2003: Heike Pfeifer; Barbara Wassmann; Wolf-Karsten Hofmann; Martina Komor; Urban J Scheuring; Patrick Brück; Anja Binckebanck; Eberhard Schleyer; Nicola Gökbuget; Thomas Wolff; Michael Lübbert; Lothar Leimer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4674-81.
2003: Walter Fiedler; Rolf M Mesters; Heike Tinnefeld; Sonja Loges; Peter Staib; Ulrich Duhrsen; Michael Flasshove; Oliver G Ottmann; Wolfram Jung; Franco Cavalli; Rolf Kuse; Joerg Thomalla; Hubert Serve; Anne-Marie O'Farrell; Mark Jacobs; Nicoletta M Brega; Paul Scigalla; Dieter K Hossfeld; Wolfgang E Berdel
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Blood 2003;102(8):2763-7.
2003: Tim Beissert; Elena Puccetti; Andrea Bianchini; Saskia Güller; Simone Boehrer; Dieter Hoelzer; Oliver G Ottmann; Clara Nervi; Martin Ruthardt
Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
Blood 2003;102(8):2985-93.
2003: Elena Puccetti; Tim Beissert; Saskia Güller; Jun E Li; Dieter Hoelzer; Oliver G Ottmann; Martin Ruthardt
Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Oncogene 2003;22(44):6900-8.
2003: Barbara Wassmann; Urban J Scheuring; Heike Pfeifer; Anja Binckebanck; A Käbisch; M Lübbert; Lothar Leimer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Leukemia 2003;17(10):1919-24.
2003: Junya Kuroda; Shinya Kimura; Hidekazu Segawa; Yutaka Kobayashi; Toshikazu Yoshikawa; Yoshimasa URASAKI; Takanori Ueda; Fumio Enjo; Harukuni Tokuda; Oliver G Ottmann; Taira Maekawa
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Blood 2003;102(6):2229-35.
2003: Urban J Scheuring; Heike Pfeifer; Barbara Wassmann; Patrick Brück; B Gehrke; Eduard K Petershofen; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Leukemia 2003;17(9):1700-6.
2003: Urban J Scheuring; Heike Pfeifer; Barbara Wassmann; Patrick Brück; Dieter Hoelzer; Oliver G Ottmann
Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Haematologica 2003;88(9):1074-6.
2003: Wolf-Karsten Hofmann; Martina Komor; Barbara Wassmann; Letetia C Jones; Harald Gschaidmeier; Dieter Hoelzer; H Phillip Koeffler; Oliver G Ottmann
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Blood 2003;102(2):659-61.
2003: Dieter Kirchner; Justus Duyster; Oliver G Ottmann; Roland M Schmid; Lothar Bergmann; Gerd Munzert
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
Experimental hematology 2003;31(6):504-11.
2003: Barbara Wassmann; Urban J Scheuring; Christian Thiede; Heike Pfeifer; Martin Bornhäuser; F Griesinger; Andreas Hochhaus; Eberhard Schleyer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Bone marrow transplantation 2003;31(7):611-4.
2003: Stefan A Klein; Susanne Karsten; Brigitte Rüster; Christian Klebba; Martine Pape; Oliver G Ottmann; Dieter Hoelzer; W Kurt Roth
Comparison of TaqMan real-time PCR and p24 Elisa for quantification of in vitro HIV-1 replication.
Journal of virological methods 2003;107(2):169-75.
2003: Urban J Scheuring; Heike Pfeifer; Barbara Wassmann; Patrick Bruck; Johannes Atta; Eduard K Petershofen; Brigitte Gehrke; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Blood 2003;101(1):85-90.
2002: Oliver G Ottmann; Barbara Wassmann
Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.
Best practice & research. Clinical haematology 2002;15(4):757-69.
2002: Elena Puccetti; Darja Obradovic; Tim Beissert; Andrea Bianchini; Birgit Washburn; Ferdinando Chiaradonna; Simone Boehrer; Dieter Hoelzer; Oliver G Ottmann; Pier Giuseppe Pelicci; Clara Nervi; Martin Ruthardt
AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor.
Cancer research 2002;62(23):7050-8.
2002: Barbara Wassmann; Heike Pfeifer; Urban J Scheuring; Stefan A Klein; Nicola Gökbuget; Anja Binckebanck; Hans Martin; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
Leukemia 2002;16(12):2358-65.
2002: Burkhard Möller; T T Nguyen; Uta Kessler; Joachim Peter Kaltwasser; Dieter Hoelzer; Oliver G Ottmann
Interleukin-10 expression: is there a neglected contribution of CD8+ T cells in rheumatoid arthritis joints?
Clinical and experimental rheumatology 2002;20(6):813-22.
2002: Dieter Hoelzer; Nicola Gökbuget; Oliver G Ottmann
Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Seminars in hematology 2002;39(4 Suppl 3):32-7.
2002: Wolf-Karsten Hofmann; Gernot Seipelt; S Langenhan; Regina Reutzel; D Schott; O Schoeffski; Hans-Jochen Illiger; Frank Hartmann; Leopold Balleisen; Astrid Franke; Friedrich Fiedler; Christoph Huber; Herbert Rasche; Lothar Bergmann; Arnold Ganser; Christiane Pott; Rita Pasold; C Rudolph; Oliver G Ottmann; Nicola Gökbuget; Dieter Hoelzer
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Annals of hematology 2002;81(10):570-4.
2002: Gesine Bug; Tanja Rossmanith; Reinhard Henschler; Leoni A Kunz-Schughart; B Schröder; Manuela Kampfmann; M Kreutz; Dieter Hoelzer; Oliver G Ottmann
Rho family small GTPases control migration of hematopoietic progenitor cells into multicellular spheroids of bone marrow stroma cells.
Journal of leukocyte biology 2002;72(4):837-45.
2002: Oliver G Ottmann; Brian J Druker; Charles L Sawyers; John M Goldman; Josy Reiffers; Richard T Silver; Sante Tura; Thomas Fischer; Michael W N Deininger; Charles Alan Schiffer; Michele Baccarani; Alois Gratwohl; Andreas Hochhaus; Dieter Hoelzer; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Stephen G O'Brien
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood 2002;100(6):1965-71.
2002: Burkhard Möller; Natasa Kukoc-Zivojnov; Noriko Koyama; S Grapenthin; Uta Kessler; Stefan A Klein; Uwe Kalina; Joachim Peter Kaltwasser; Dieter Hoelzer; Oliver G Ottmann
Prednisolone induces interleukin-18 expression in mononuclear blood and myeloid progenitor cells.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2002;51(9):457-63.
2002: Marion G Ott; Heike Merget-Millitzer; Oliver G Ottmann; Hans Martin; Nicole Brüggenolte; Heike Bialek; Reinhard Seger; Johann Peter Hossle; Dieter Hoelzer; Manuel Grez
Mobilization and transduction of CD34(+) peripheral blood stem cells in patients with X-linked chronic granulomatous disease.
Journal of hematotherapy & stem cell research 2002;11(4):683-94.
2002: Burkhard Möller; Natasa Kukoc-Zivojnov; Stella Okamgba; Uta Kessler; Elena Puccetti; Oliver G Ottmann; Joachim Peter Kaltwasser; Dieter Hoelzer; Martin Ruthardt
Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors.
Rheumatology international 2002;22(2):60-7.
2002: Katharina Schroeder; Steffen Koschmieder; Oliver G Ottmann; Dieter Hoelzer; Hansjörg Hauser; Peter P Mueller
Coordination of cell growth in cocultures by a genetic proliferation control system.
Biotechnology and bioengineering 2002;78(3):346-52.
2002: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; françois guilhot; Charles Alan Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
2002: Wolf-Karsten Hofmann; Letetia C Jones; Nathan Lemp; Sven de Vos; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann; H Phillip Koeffler
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Blood 2002;99(5):1860-2.
2002: Wolf-Karsten Hofmann; Sven de Vos; David Elashoff; Harald Gschaidmeier; Dieter Hoelzer; H Phillip Koeffler; Oliver G Ottmann
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.
Lancet 2002;359(9305):481-6.
2002: Oliver G Ottmann; Barbara Wassmann; Dieter Hoelzer
[Therapy of Philadelphia chromosome positive acute lymphatic leukemia (Ph+ ALL) with an inhibitor of abl-tyrosine kinase (Glivec)].
Medizinische Klinik (Munich, Germany : 1983) 2002;97 Suppl 1():16-21.
2002: Oliver G Ottmann; Barbara Wassmann; Dieter Hoelzer
Imatinib for relapsed BCR/ABL positive leukemias.
Annals of hematology 2002;81 Suppl 2():S36-7.
2002: Dieter Hoelzer; Nicola Gökbuget; Oliver G Ottmann; Ching-Hon Pui; Mary Relling; Frederick R Appelbaum; Jacques J M van Dongen; Tomasz Szczepański
Acute lymphoblastic leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():162-92.
2002: Oliver G Ottmann; Dieter Hoelzer
The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
The hematology journal : the official journal of the European Haematology Association / EHA 2002;3(1):2-6.
2002: Burkhard Möller; Uta Kessler; Stefan Rehart; Uwe Kalina; Oliver G Ottmann; Joachim Peter Kaltwasser; Dieter Hoelzer; Natasa Kukoc-Zivojnov
Expression of interleukin-18 receptor in fibroblast-like synoviocytes.
Arthritis research 2002;4(2):139-44.
2001: Barbara Wassmann; Stefan A Klein; Urban J Scheuring; Heike Pfeifer; Hans Martin; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Bone marrow transplantation 2001;28(7):721-4.
2001: Steffen Koschmieder; Wolf-Karsten Hofmann; J Kunert; Sandra Wagner; K Ballas; Gernot Seipelt; Dieter Hoelzer; Oliver G Ottmann; Uwe Kalina
TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS.
Leukemia 2001;15(6):942-9.
2001: Uwe Kalina; Steffen Koschmieder; Wolf-Karsten Hofmann; Sandra Wagner; D Kauschat; Dieter Hoelzer; Oliver G Ottmann
Transforming growth factor-beta1 interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells.
Experimental hematology 2001;29(5):602-8.
2001: Burkhard Möller; Natasa Kukoc-Zivojnov; Uta Kessler; Stefan Rehart; Joachim Peter Kaltwasser; Dieter Hoelzer; Uwe Kalina; Oliver G Ottmann
Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis.
Rheumatology (Oxford, England) 2001;40(3):302-9.
2001: Elena Puccetti; B Sennewald; F Fosca-Ferrara; Simone Boehrer; Andrea Bianchini; Dieter Hoelzer; Oliver G Ottmann; Clara Nervi; Martin Ruthardt
Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.
The hematology journal : the official journal of the European Haematology Association / EHA 2001;2(6):385-92.
2001: Tanja Rossmanith; B Schröder; Gesine Bug; P Müller; T Klenner; R Knaus; Dieter Hoelzer; Oliver G Ottmann
Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cells.
Stem cells (Dayton, Ohio) 2001;19(4):313-20.
2001: Steffen Koschmieder; Gesine Bug; B Schröder; Tanja Rossmanith; Wolf-Karsten Hofmann; Uwe Kalina; Dieter Hoelzer; Oliver G Ottmann
Murine M2-10B4 and SL/SL cell lines differentially affect the balance between CD34+ cell expansion and maturation.
International journal of hematology 2001;73(1):71-7.
2000: Uwe Kalina; K Ballas; Noriko Koyama; D Kauschat; C Miething; Joachim Arnemann; H Martin; Dieter Hoelzer; Oliver G Ottmann
Genomic organization and regulation of the human interleukin-18 gene.
Scandinavian journal of immunology 2000;52(6):525-30.
2000: Ulrich Mahlknecht; S Schnittger; Oliver G Ottmann; Claudia Schoch; M Mosebach; Wolfgang Hiddemann; Dieter Hoelzer
Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5).
Biochimica et biophysica acta 2000;1493(3):342-8.
2000: Uwe Kalina; Wolf-Karsten Hofmann; Steffen Koschmieder; Sandra Wagner; D Kauschat; Dieter Hoelzer; Oliver G Ottmann
Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.
Experimental hematology 2000;28(10):1158-63.
2000: Uwe Kalina; D Kauschat; Noriko Koyama; H Nuernberger; K Ballas; Steffen Koschmieder; Gesine Bug; Wolf-Karsten Hofmann; Dieter Hoelzer; Oliver G Ottmann
IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(3):1307-13.
2000: Elena Puccetti; Saskia Güller; Annette Orleth; Nicole Brüggenolte; Dieter Hoelzer; Oliver G Ottmann; Martin Ruthardt
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Cancer research 2000;60(13):3409-13.
2000: Wolf-Karsten Hofmann; Uwe Kalina; Steffen Koschmieder; Gernot Seipelt; Dieter Hoelzer; Oliver G Ottmann
Defective megakaryocytic development in myelodysplastic syndromes.
Leukemia & lymphoma 2000;38(1-2):13-9.
2000: Wolf-Karsten Hofmann; Gernot Seipelt; Oliver G Ottmann; Uwe Kalina; Steffen Koschmieder; J Brücher; N Frickhofen; M Klausmann; Paris S Mitrou; Dieter Hoelzer
Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels.
Annals of hematology 2000;79(5):255-8.
2000: Gernot Seipelt; Oliver G Ottmann; Dieter Hoelzer
Cytokine therapy for myelodysplastic syndrome.
Current opinion in hematology 2000;7(3):156-60.
2000: Stefan A Klein; Christian Klebba; D Kauschat; Martine Pape; L Ozmen; Dieter Hoelzer; Oliver G Ottmann; Uwe Kalina
Interleukin-18 stimulates HIV-1 replication in a T-cell line.
European cytokine network 2000;11(1):47-52.
2000: Christian Klebba; Oliver G Ottmann; Michaela Scherr; Martine Pape; Joachim W Engels; Manuel Grez; Dieter Hoelzer; Stefan A Klein
Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro.
Gene therapy 2000;7(5):408-16.
1999: Thomas Sternsdorf; Elena Puccetti; Kirsten Jensen; Dieter Hoelzer; Hans Will; Oliver G Ottmann; Martin Ruthardt
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Molecular and cellular biology 1999;19(7):5170-8.
1999: Stefan A Klein; Oliver G Ottmann; K Ballas; Thomas S Dobmeyer; Martine Pape; E Weidmann; Dieter Hoelzer; Uwe Kalina
Quantification of human interleukin 18 mRNA expression by competitive reverse transcriptase polymerase chain reaction.
Cytokine 1999;11(6):451-8.
1999: Wolf-Karsten Hofmann; Uwe Kalina; Gernot Seipelt; K Hoffmann; Sandra Wagner; Dieter Hoelzer; Oliver G Ottmann
Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha.
European journal of haematology 1999;62(5):336-40.
1999: Wolf-Karsten Hofmann; Oliver G Ottmann; Dieter Hoelzer
Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
Leukemia 1999;13 Suppl 1():S14-8.
1999: Wolf-Karsten Hofmann; Arnold Ganser; Gernot Seipelt; Oliver G Ottmann; C Zander; G Geissler; K Hoffmann; K Höffken; JT Fischer; G Isele; Dieter Hoelzer
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
Annals of hematology 1999;78(3):125-30.
1999: Wolf-Karsten Hofmann; Uwe Kalina; Sandra Wagner; Gernot Seipelt; C Ries; Dieter Hoelzer; Oliver G Ottmann
Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes.
Experimental hematology 1999;27(3):395-400.
1999: Wolf-Karsten Hofmann; Oliver G Ottmann; Dieter Hoelzer
Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
Leukemia 1999;13(1):14-8.
1998: Oliver G Ottmann; Dieter Hoelzer
Growth factors in the treatment of acute lymphoblastic leukemia.
Leukemia research 1998;22(12):1171-8.
1998: Andrea Schilz; Gaby Brouns; H Knöss; Oliver G Ottmann; Dieter Hoelzer; Axel A Fauser; Adrian J Thrasher; Manuel Grez
High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions.
Blood 1998;92(9):3163-71.
1998: Gernot Seipelt; Wolf-Karsten Hofmann; H Martin; Barbara Wassmann; A Boehme; Oliver G Ottmann; Dieter Hoelzer
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
Annals of hematology 1998;76(3-4):145-51.
1997: Oliver G Ottmann; Gernot Seipelt; Dieter Hoelzer
[Clinical administration of hematopoietic growth factors. When and where?].
Der Internist 1997;38(12):1160-7.
1997: Stefan A Klein; JM Dobmeyer; Thomas S Dobmeyer; Martine Pape; Oliver G Ottmann; Eilke B Helm; Dieter Hoelzer; R Rossol
Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry.
AIDS (London, England) 1997;11(9):1111-8.
1996: Wolf-Karsten Hofmann; Oliver G Ottmann; Arnold Ganser; Dieter Hoelzer
Myelodysplastic syndromes: clinical features.
Seminars in hematology 1996;33(3):177-85.
1996: RG Geissler; R Rossol; U Mentzel; Oliver G Ottmann; A S Klein; Peter Gute; E B Helm; Dieter Hoelzer; Arnold Ganser
Gamma delta-T cell-receptor-positive lymphocytes inhibit human hematopoietic progenitor cell growth in HIV type 1-infected patients.
AIDS research and human retroviruses 1996;12(7):577-84.
1996: Arnold Ganser; A Maurer; C Contzen; Gernot Seipelt; Oliver G Ottmann; C Schadeck-Gressel; K Kolbe; R Haas; C Zander; R Reutzel; Dieter Hoelzer
Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol.
Annals of hematology 1996;72(4):237-44.
1995: Oliver G Ottmann; Dieter Hoelzer; E Gracien; Arnold Ganser; K Kelly; R Reutzel; T Lipp; F W Busch; M Schwonzen; Gerhard Heil
Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial.
Blood 1995;86(2):444-50.
1995: A B Maurer; Arnold Ganser; Gernot Seipelt; Oliver G Ottmann; U Mentzel; G R Geissler; Dieter Hoelzer
Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors.
British journal of haematology 1995;89(3):449-56.
1994: RG Geissler; Arnold Ganser; Oliver G Ottmann; Peter Gute; A Morawetz; P Guba; Eilke B Helm; Dieter Hoelzer
In vitro improvement of bone marrow-derived hematopoietic colony formation in HIV-positive patients by alpha-D-tocopherol and erythropoietin.
European journal of haematology 1994;53(4):201-6.
1994: Gernot Seipelt; Arnold Ganser; H Duranceyk; A Maurer; Oliver G Ottmann; Dieter Hoelzer
Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment.
Annals of hematology 1994;68(4):167-70.
1994: Arnold Ganser; Gernot Seipelt; W Verbeek; Oliver G Ottmann; A Maurer; K Kolbe; U Hess; S Elsner; R Reutzel; B Wörmann
Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes.
Leukemia 1994;8(3):369-75.
1993: A B Maurer; Arnold Ganser; R Buhl; Gernot Seipelt; Oliver G Ottmann; U Mentzel; RG Geissler; Dieter Hoelzer
Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3.
Leukemia 1993;7(11):1728-33.
1993: Arnold Ganser; Oliver G Ottmann; Dieter Hoelzer
Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implications.
Stem cells (Dayton, Ohio) 1993;11(6):465-73.
1993: Oliver G Ottmann; Arnold Ganser; M Freund; Gerhard Heil; W Hiddemann; W Heit; E Gracien; Dieter Hoelzer
Simultaneous administration of granulocyte colony-stimulating factor (Filgrastim) and induction chemotherapy in acute lymphoblastic leukemia. A pilot study.
Annals of hematology 1993;67(4):161-7.
1993: Gernot Seipelt; Arnold Ganser; H Duranceyk; A Maurer; Oliver G Ottmann; Dieter Hoelzer
Induction of TNF-alpha in patients with myelodysplastic syndromes undergoing treatment with interleukin-3.
British journal of haematology 1993;84(4):749-51.
1993: Arnold Ganser; Oliver G Ottmann; Gernot Seipelt; A Lindemann; U Hess; G Geissler; A Maurer; J Frisch; G Schulz; Roland Mertelsmann
Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes.
Leukemia 1993;7(5):696-701.
1993: RG Geissler; Oliver G Ottmann; K Kleiner; U Mentzel; A Bickelhaupt; Dieter Hoelzer; Arnold Ganser
Decreased haematopoietic colony growth in long-term bone marrow cultures of HIV-positive patients.
Research in virology 1993;144(1):69-73.
1992: Matthias Eder; Oliver G Ottmann; T E Hansen-Hagge; C R Bartram; S Falk; S Gillis; Dieter Hoelzer; Arnold Ganser
In vitro culture of common acute lymphoblastic leukemia blasts: effects of interleukin-3, interleukin-7, and accessory cells.
Blood 1992;79(12):3274-84.
1992: Arnold Ganser; A Lindemann; Oliver G Ottmann; Gernot Seipelt; U Hess; G Geissler; Lothar Kanz; J Frisch; G Schulz; F Herrmann
Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study.
Blood 1992;79(10):2583-91.
1992: C Schardt; Oliver G Ottmann; Dieter Hoelzer; Arnold Ganser
Acute lymphoblastic leukemia with the (4;11) translocation: combined cytogenetic, immunological and molecular genetic analyses.
Leukemia 1992;6(5):370-4.
1992: RG Geissler; Oliver G Ottmann; G Kojouharoff; P Reutzel; Matthias Eder; Dieter Hoelzer; Arnold Ganser
Influence of human recombinant interferon-alpha and interferon-gamma on bone marrow progenitor cells of HIV-positive individuals.
AIDS research and human retroviruses 1992;8(4):521-5.
1992: Arnold Ganser; Gernot Seipelt; Matthias Eder; G Geissler; Oliver G Ottmann; U Hess; Dieter Hoelzer
Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs.
Seminars in oncology 1992;19(2 Suppl 4):95-101.
1992: U Hess; Arnold Ganser; H G Schnürch; Gernot Seipelt; Oliver G Ottmann; S Falk; G Schulz; Dieter Hoelzer
Myelokathexis treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).
British journal of haematology 1992;80(2):254-6.
1991: RG Geissler; Arnold Ganser; Oliver G Ottmann; G Kojouharoff; P Reutzel; Koen Andries; K Schellekens; Dieter Hoelzer
TIBO R82913, a new HIV-1 inhibiting agent, does not inhibit hematopoietic progenitor cells.
AIDS research and human retroviruses 1991;7(12):1021-3.
1991: Arnold Ganser; Oliver G Ottmann; Gernot Seipelt; U Hess; G Geissler; Rolf Merget; S Falk; A Maurer; Matthias Eder; Dieter Hoelzer
Preclinical and clinical evaluation of interleukin 3.
Behring Institute Mitteilungen 1991;(90):50-61.
1991: Oliver G Ottmann; C C Stella; Matthias Eder; P Reutzel; S Ströcker; Dieter Hoelzer; Arnold Ganser
Regulation of early hematopoiesis in serum-deprived cultures of mafosfamide-treated and untreated CD34-enriched bone marrow cells.
Experimental hematology 1991;19(8):773-8.
1991: Arnold Ganser; J W Janssen; Oliver G Ottmann; Gernot Seipelt; Matthias Eder; R Becher; A Lindermann; F Herrmann; G Schulz; Roland Mertelsmann
In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders.
Leukemia 1991;5(6):487-92.
1991: RG Geissler; Oliver G Ottmann; Matthias Eder; G Kojouharoff; Dieter Hoelzer; Arnold Ganser
Effect of recombinant human transforming growth factor beta and tumor necrosis factor alpha on bone marrow progenitor cells of HIV-infected persons.
Annals of hematology 1991;62(5):151-5.
1991: S Falk; Gernot Seipelt; Arnold Ganser; Oliver G Ottmann; Dieter Hoelzer; HJ Stutte; K Hübner
Bone marrow findings after treatment with recombinant human interleukin-3.
American journal of clinical pathology 1991;95(3):355-62.
1991: G Kojouharoff; Oliver G Ottmann; H von Briesen; G Geissler; H Rübsamen-Waigmann; Dieter Hoelzer; Arnold Ganser
Infection of granulocyte/monocyte progenitor cells with HIV1.
Research in virology 1991;142(2-3):151-7.
1991: Arnold Ganser; A Lindemann; Gernot Seipelt; Oliver G Ottmann; F Herrmann; Matthias Eder; J Frisch; G Schulz; Roland Mertelsmann; Dieter Hoelzer
Clinical effects of recombinant human interleukin-3.
American journal of clinical oncology 1991;14 Suppl 1():S51-63.
1991: Arnold Ganser; A Lindemann; Gernot Seipelt; Oliver G Ottmann; Matthias Eder; F Herrmann; J Frisch; G Schulz; Roland Mertelsmann; Dieter Hoelzer
Recombinant human interleukin-3 in patients with hematopoietic failure.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1991;121():162-72.
1991: Arnold Ganser; Oliver G Ottmann; Gernot Seipelt; Matthias Eder; G Geissler; Rolf Merget; A Maurer; S Falk; A Lindemann; F Herrmann
Results of phase I/II trials with recombinant human interleukin-3.
Biotechnology therapeutics 1991;2(3-4):313-25.
1991: F Herrmann; Roland Mertelsmann; A Lindemann; Oliver G Ottmann; Gernot Seipelt; Wolfgang Oster; Dieter Hoelzer; Arnold Ganser
Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
Biotechnology therapeutics 1991;2(3-4):299-311.
1990: Oliver G Ottmann; Arnold Ganser; Gernot Seipelt; Matthias Eder; G Schulz; Dieter Hoelzer
Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo.
Blood 1990;76(8):1494-502.
1990: Arnold Ganser; A Lindemann; Gernot Seipelt; Oliver G Ottmann; Matthias Eder; S Falk; F Herrmann; Joachim Peter Kaltwasser; P Meusers; M Klausmann
Effects of recombinant human interleukin-3 in aplastic anemia.
Blood 1990;76(7):1287-92.
1990: Arnold Ganser; A Lindemann; Gernot Seipelt; Oliver G Ottmann; F Herrmann; Matthias Eder; J Frisch; G Schulz; Roland Mertelsmann; Dieter Hoelzer
Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure.
Blood 1990;76(4):666-76.
1990: Matthias Eder; Oliver G Ottmann; T E Hansen-Hagge; C R Bartram; S Gillis; Dieter Hoelzer; Arnold Ganser
Effects of recombinant human IL-7 on blast cell proliferation in acute lymphoblastic leukemia.
Leukemia 1990;4(8):533-40.
1990: Arnold Ganser; Gernot Seipelt; A Lindemann; Oliver G Ottmann; S Falk; Matthias Eder; F Herrmann; R Becher; K Höffken; T Büchner
Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.
Blood 1990;76(3):455-62.
1990: Arnold Ganser; Oliver G Ottmann; H von Briesen; B Völkers; H Rübsamen-Waigmann; Dieter Hoelzer
Changes in the haematopoietic progenitor cell compartment in the acquired immunodeficiency syndrome.
Research in virology 1990;141(2):185-93.
1990: Dieter Hoelzer; Arnold Ganser; Oliver G Ottmann; K Höffken; R Becher; D Lutz; O Krieger; V Diehl; B Lathan; M A Boogaerts
Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes.
Haematology and blood transfusion 1990;33():763-9.
1990: Gernot Seipelt; Oliver G Ottmann; Arnold Ganser; Matthias Eder; A Lindemann; S Falk; HJ Stutte; K Hübner; Roland Mertelsmann; Dieter Hoelzer
[In vitro and in vivo effects of recombinant human interleukin-3 on hematopoietic progenitor cells].
Verhandlungen der Deutschen Gesellschaft für Pathologie 1990;74():116-9.
1990: Rolf Merget; A B Maurer; U Koch; Arnold Ganser; Oliver G Ottmann; Gerhard Schultze-Werninghaus; Gernot Seipelt; W Zachgo; Dieter Hoelzer; J Meier-Sydow
Histamine release from basophils after in vivo application of recombinant human interleukin-3 in man.
International archives of allergy and applied immunology 1990;92(4):366-74.
1989: Arnold Ganser; Oliver G Ottmann; H Erdmann; G Schulz; Dieter Hoelzer
The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity in chronic severe neutropenia.
Annals of internal medicine 1989;111(11):887-92.
1989: Arnold Ganser; Oliver G Ottmann; G Schulz; Dieter Hoelzer
Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study.
Onkologie 1989;12(1):13-5.
1989: Arnold Ganser; B Völkers; J Greher; Oliver G Ottmann; F Walther; R Becher; Lothar Bergmann; G Schulz; Dieter Hoelzer
Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial.
Blood 1989;73(1):31-7.